Darbepoetin alfa (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Darbepoetin alfa" in English language version.

refsWebsite

Global rank English rank

9nih.gov

4^th place

6web.archive.org

1^st place

4fda.gov

447^th place

338^th place

3doi.org

2^nd place

2europa.eu

68^th place

117^th place

1drugs.com

399^th place

333^rd place

1handle.net

102^nd place

76^th place

1nytimes.com

7^th place

1amgen.com

low place

1asco.org

low place

1bbc.co.uk

8^th place

10^th place

1labusinessjournal.com

low place

6,428^th place

1reuters.com

49^th place

47^th place

amgen.com

investors.amgen.com

Amgen (2007). "Amgen 2007 Annual Report and Financial Summary". Archived from the original on 24 January 2022. Retrieved 24 January 2022.

asco.org

Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. (November 2010). "American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer". Journal of Clinical Oncology. 28 (33): 4996–5010. doi:10.1200/jco.2010.29.2201. PMC 2988667. PMID 20975064. Archived from the original on 3 November 2014.

bbc.co.uk

news.bbc.co.uk

McGrath M, Portal G (30 January 2002). "New drugs give cheats the edge". BBC News Online. Retrieved 3 November 2014.

doi.org

Smith RE, Jaiyesimi IA, Meza LA, Tchekmedyian NS, Chan D, Griffith H, et al. (April 2001). "Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer". British Journal of Cancer. 84 (Suppl 1): 24–30. doi:10.1054/bjoc.2001.1749. PMC 2363901. PMID 11308271.
Wauters I, Pat K, Vansteenkiste J (June 2006). "Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia". Therapeutics and Clinical Risk Management. 2 (2): 175–186. doi:10.2147/tcrm.2006.2.2.175. PMC 1661657. PMID 18360591.
Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. (November 2010). "American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer". Journal of Clinical Oncology. 28 (33): 4996–5010. doi:10.1200/jco.2010.29.2201. PMC 2988667. PMID 20975064. Archived from the original on 3 November 2014.

drugs.com

"Darbepoetin alfa (Aranesp) Use During Pregnancy". Drugs.com. 31 December 2018. Retrieved 7 April 2020.

europa.eu

ema.europa.eu

"Aranesp EPAR". European Medicines Agency. 8 June 2001. Retrieved 29 June 2024.

emea.europa.eu

"European Public Assessment Report (Abstract)" (PDF). European Medicines Agency. 8 June 2001. Archived from the original (PDF) on 17 October 2006. Retrieved 27 January 2007.

fda.gov

Siegel JP (17 September 2001). "Product Approval Information - Licensing Action". United States Food and Drug Administration. Archived from the original on 22 October 2006. Retrieved 27 January 2007.
"FDA Public Health Advisory: Erythropoiesis-Stimulating Agents (ESAs): Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp)". Food and Drug Administration. Archived from the original on 28 May 2007. Retrieved 5 June 2007.
"Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA)". Food and Drug Administration. Archived from the original on 15 May 2007. Retrieved 5 June 2007.

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

handle.net

hdl.handle.net

World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

labusinessjournal.com

staff-author (14 March 2007). "FDA to Study Amgen Drugs". Los Angeles Business Journal. Retrieved 8 June 2024.

nih.gov

ncbi.nlm.nih.gov

Smith RE, Jaiyesimi IA, Meza LA, Tchekmedyian NS, Chan D, Griffith H, et al. (April 2001). "Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer". British Journal of Cancer. 84 (Suppl 1): 24–30. doi:10.1054/bjoc.2001.1749. PMC 2363901. PMID 11308271.
Vest LS, Patel P, Patel JB (June 2024). "Epoetin Alfa". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 32119434.
Wauters I, Pat K, Vansteenkiste J (June 2006). "Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia". Therapeutics and Clinical Risk Management. 2 (2): 175–186. doi:10.2147/tcrm.2006.2.2.175. PMC 1661657. PMID 18360591.
Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. (November 2010). "American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer". Journal of Clinical Oncology. 28 (33): 4996–5010. doi:10.1200/jco.2010.29.2201. PMC 2988667. PMID 20975064. Archived from the original on 3 November 2014.

pubmed.ncbi.nlm.nih.gov

Smith RE, Jaiyesimi IA, Meza LA, Tchekmedyian NS, Chan D, Griffith H, et al. (April 2001). "Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer". British Journal of Cancer. 84 (Suppl 1): 24–30. doi:10.1054/bjoc.2001.1749. PMC 2363901. PMID 11308271.
Vest LS, Patel P, Patel JB (June 2024). "Epoetin Alfa". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 32119434.
Wauters I, Pat K, Vansteenkiste J (June 2006). "Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia". Therapeutics and Clinical Risk Management. 2 (2): 175–186. doi:10.2147/tcrm.2006.2.2.175. PMC 1661657. PMID 18360591.
Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. (November 2010). "American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer". Journal of Clinical Oncology. 28 (33): 4996–5010. doi:10.1200/jco.2010.29.2201. PMC 2988667. PMID 20975064. Archived from the original on 3 November 2014.

dailymed.nlm.nih.gov

"Aranesp- darbepoetin alfa injection, solution Aranesp- darbepoetin alfa solution". DailyMed. Retrieved 7 April 2020.

nytimes.com

Pollack A (26 January 2007). "Amgen Finds Anemia Drug Holds Risks in Cancer Use". The New York Times. Retrieved 27 January 2007.

reuters.com

fr.reuters.com

[1]^{[dead link‍]}

web.archive.org

Siegel JP (17 September 2001). "Product Approval Information - Licensing Action". United States Food and Drug Administration. Archived from the original on 22 October 2006. Retrieved 27 January 2007.
"European Public Assessment Report (Abstract)" (PDF). European Medicines Agency. 8 June 2001. Archived from the original (PDF) on 17 October 2006. Retrieved 27 January 2007.
Amgen (2007). "Amgen 2007 Annual Report and Financial Summary". Archived from the original on 24 January 2022. Retrieved 24 January 2022.
"FDA Public Health Advisory: Erythropoiesis-Stimulating Agents (ESAs): Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp)". Food and Drug Administration. Archived from the original on 28 May 2007. Retrieved 5 June 2007.
"Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA)". Food and Drug Administration. Archived from the original on 15 May 2007. Retrieved 5 June 2007.
Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. (November 2010). "American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer". Journal of Clinical Oncology. 28 (33): 4996–5010. doi:10.1200/jco.2010.29.2201. PMC 2988667. PMID 20975064. Archived from the original on 3 November 2014.